Pre-made Befovacimab benchmark antibody ( Whole mAb, anti-TFPI therapeutic antibody, Anti-EPI/LACI/TFI Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-053

Pre-Made Befovacimab biosimilar, Whole mAb, Anti-TFPI Antibody: Anti-EPI/LACI/TFI therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Befovacimab (formerly BAY 1093884) is an anti-tissue factor pathway inhibitor (anti-TFPI) antibody being developed by Bayer for the treatment of haemophilia.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-053-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Befovacimab biosimilar, Whole mAb, Anti-TFPI Antibody: Anti-EPI/LACI/TFI therapeutic antibody
INN Name Befovacimab
TargetTFPI
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
Companiesna
Conditions Approvedna
Conditions ActiveHaemophilia
Conditions Discontinuedna
Development Techna